The Role of NF-κB in Inflammatory Diseases

  • E. Andreakos
  • I. Udalova
  • S. Sacre
  • B. M. Foxwell
Chapter

Abstract

The term inflammation was used as early as 1600 BC in Egyptian papyrus writings to describe a complex series of events induced by a wound or an infection. These events can be recognized by the redness, swelling, fever and pain observed, and are now known to reflect the vasodilation, increased capillary permeability and influx of phagocytic cells. Thus, under most circumstances, inflammation is a normal physiological and very beneficial response, employed by our organism to fight infectious agents and protect us from disease. Inflammation involves the activation of both the innate and adaptive branches of the immune system and is under the control of a large number of cellular and molecular components. Major cellular components include B-cells, T-cells, dendritic cells and macrophages (Table 1).

Keywords

NFKB Acti Rheumatoid Synovium TNFa Promoter Lymphoid Organ Development Lamina Propria Macrophage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T & Thanos D (2000) Ordered recruitment of chromatin modifying and general transcription factors to the IFN-β promoter. Cell 103: 667–678.PubMedCrossRefGoogle Scholar
  2. Ahmad M, Theofanidis P & Medford RM (1998) Role of activating protein-1 in the regulation of the vascular cell adhesion molecule-1 gene expression by tumor necrosis factor-α. J. Biol. Chem. 273: 4616–4621.PubMedCrossRefGoogle Scholar
  3. Allport VC, Slater DM, Newton R & Bennett PR (2000) NF-κB and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol. Hum. Reprod. 6: 561–565.PubMedCrossRefGoogle Scholar
  4. Andreakos E, Foxwell B, Brennan F, Maini R & Feldmann M (2002) Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev. 13: 299–314.PubMedCrossRefGoogle Scholar
  5. Asadullah K, Volk HD & Sterry W (2002) Novel immunotherapies for psoriasis. Trends Immunol. 23: 47–53.PubMedCrossRefGoogle Scholar
  6. Asahara H, Asanuma M, Ogawa N, Nishibayashi S & Inoue H (1995) High DNA-binding activity of transcription factor NF-κB in synovial membranes of patients with rheumatoid arthritis. Biochem. Mol. Biol. Int. 37: 827–832.PubMedGoogle Scholar
  7. Auphan N, DiDonato JA, Rosette C, Helmberg A & Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270: 286–290.PubMedCrossRefGoogle Scholar
  8. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S & Johnson PF (1998) Tumor necrosis factor α transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-κB p50. Mol. Cell. Biol. 18: 5678–5689.PubMedGoogle Scholar
  9. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J & Mattson MP (1995) Tumor necrosis factors α and β protect neurons against amyloid β-peptide toxicity: evidence for involvement of a κB-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. USA 92: 9328–9332.PubMedCrossRefGoogle Scholar
  10. Barger SW & Mattson MP (1996) Induction of neuroprotective κB-dependent transcription by secreted forms of the Alzheimer’s β-amyloid precursor. Brain Res. Mol. Brain Res. 40: 116–126.PubMedCrossRefGoogle Scholar
  11. Barnes PJ & Adcock IM (1997) NF-κB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol. Sci. 18: 46–50.PubMedCrossRefGoogle Scholar
  12. Barnes PJ & Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336: 1066–1071.PubMedCrossRefGoogle Scholar
  13. Beg AA, Sha WC, Bronson RT, Ghosh S & Baltimore D (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376: 167–170.PubMedCrossRefGoogle Scholar
  14. Beg AA & Baltimore D (1996) An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274: 782–784.PubMedCrossRefGoogle Scholar
  15. Belich MP, Salmeron A, Johnston LH & Ley SC (1999) TPL-2 kinase regulates the proteolysis of the NF-AκB-inhibitory protein NF-κB1 p105. Nature 397: 363–368.PubMedCrossRefGoogle Scholar
  16. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E & Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50: 2792–2808.PubMedCrossRefGoogle Scholar
  17. Blackwell TS, Blackwell TR, Holden EP, Christman BW & Christman JW (1996) In vivo antioxidant treatment suppresses nuclear factor-κB activation and neutrophilic lung inflammation. J. Immunol. 157: 1630–1637.PubMedGoogle Scholar
  18. Blackwell TS & Christman JW (1997) The role of nuclear factor-κB in cytokine gene regulation. Am. J. Respir. Cell Mol. Biol. 17: 3–9.PubMedGoogle Scholar
  19. Blackwell TS, Yull FE, Chen CL, Venkatakrishnan A, Blackwell TR, Hicks DJ, Lancaster LH, Christman JW & Kerr LD (1999) Use of genetically altered mice to investigate the role of nuclear factor-κB activation and cytokine gene expression in sepsis-induced ARDS. Chest 116: 73S–74S.PubMedCrossRefGoogle Scholar
  20. Bogdan C (2001) Nitric oxide and the immune response. Nat. Immunol. 2: 907–916.PubMedCrossRefGoogle Scholar
  21. Bondeson J, Foxwell B, Brennan F & Feldmann M (1999) Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl. Acad. Sci. USA 96: 5668–5673.PubMedCrossRefGoogle Scholar
  22. Bonetti B, Pohl J, Gao YL & Raine CS (1997) Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J. Immunol. 159: 5733–5741.PubMedGoogle Scholar
  23. Bonetti B & Raine CS (1997) Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42: 74–84.PubMedCrossRefGoogle Scholar
  24. Bonetti B, Stegagno C, Cannella B, Rizzuto N, Moretto G & Raine CS (1999) Activation of NF-κB and c-jun transcription factors in multiple sclerosis lesionslmplications for oligodendrocyte pathology. Am. J. Pathol. 155: 1433–1438.PubMedCrossRefGoogle Scholar
  25. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K & Siebenlist U (1993) The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 72: 729–739.PubMedCrossRefGoogle Scholar
  26. Brand K, Page S, Rogler G, Bartsch A, Brandi R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA & Neumeier D (1996) Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J. Clin. Invest. 97: 1715–1722.PubMedCrossRefGoogle Scholar
  27. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, Kaltschmidt C, Neumann FJ, Mackman N, Baeurele PA, Walli AK & Neumeier D (1997) Dysregulation of monocytic nuclear factor-κB by oxidized low-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 17: 1901–1909.PubMedCrossRefGoogle Scholar
  28. Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K & Scholmerich J (1997) Treatment of active and postactive ileal and colonic Crohn’s disease with oral pH-modified-release budesonide. German Budesonide Study Group. Hepatogastroenterology 44: 445–451.PubMedGoogle Scholar
  29. Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, Palinski W, Shah PK, Cercek B, Nilsson J & Regnstrom J (1998) An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler. Thromb. Vasc. Biol. 18: 884–893.PubMedCrossRefGoogle Scholar
  30. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA & Van der Saag PT (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9: 401–412.PubMedCrossRefGoogle Scholar
  31. Campbell IK, Gerondakis S, O’Donnell K & Wicks IP (2000) Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J. Clin. Invest. 105: 1799–1806.PubMedCrossRefGoogle Scholar
  32. Carey M (1998) The enhanceosome and transcriptional synergy. Cell 92: 5–8.PubMedCrossRefGoogle Scholar
  33. Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Baeuerle PA & Barde YA (1996) Selective activation of NF-κB by nerve growth factor through the neurotrophin receptor p75. Science 272: 542–545.PubMedCrossRefGoogle Scholar
  34. Chang L & Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–40.PubMedCrossRefGoogle Scholar
  35. Chin AI, Dempsey PW, Bruhn K, Miller JF, Xu Y & Cheng G (2002) Involvement of receptor-interacting protein 2 in innate and adaptive immune responses. Nature 416: 190–194.PubMedCrossRefGoogle Scholar
  36. Christman JW, Lancaster LH & Blackwell TS (1998) Nuclear factor κB: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 24: 1131–1138.PubMedCrossRefGoogle Scholar
  37. Christman JW, Sadikot RT & Blackwell TS (2000) The role of nuclear factor-κB in pulmonary diseases. Chest 117: 1482–1487.PubMedCrossRefGoogle Scholar
  38. Ciechanover A, Gonen H, Bercovich B, Cohen S, Fajerman I, Israel A, Mercurio F, Kahana C, Schwartz AL, Iwai K & Orian A (2001) Mechanisms of ubiquitin-mediated limited processing of the NF-κB1 precursor protein p105. Biochimie 83: 341–349.PubMedCrossRefGoogle Scholar
  39. Collins T & Cybulsky MI (2001) NF-κB: pivotal mediator or innocent bystander in atherogenesis? J. Clin. Invest. 107: 255–264.PubMedCrossRefGoogle Scholar
  40. Conron M, Bondeson J, Pantelidis P, Beynon HL, Feldmann M, duBois RM & Foxwell BM (2001) Alveolar macrophages and T cells from sarcoid but not normal lung are permissive to adenovirus infection and allow analysis of NF-κB-dependent signaling pathways. Am. J. Respir. Cell. Mol. Biol. 25: 141–149.PubMedGoogle Scholar
  41. Conron M, Andreakos E, Pantelidis P, Smith C, Beynon HL, Dubois RM & Foxwell BM (2002) Nuclear factor-κB activation in alveolar macrophages requires IκB kinase-β but not nuclear factor-κB inducing kinase. Am. J. Respir. Crit. Care Med. 165: 996–1004.PubMedGoogle Scholar
  42. Couture R, Harrisson M, Vianna RM & Cloutier F (2001) Kinin receptors in pain and inflammation. Eur. J. Pharmacol. 429: 161–176.PubMedCrossRefGoogle Scholar
  43. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT & Mclnnes IB (2000) Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 43: 1244–1256.PubMedCrossRefGoogle Scholar
  44. Darville MI & Eizirik DL (2001) Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-κB and C/EBP. Diabetes 50: 1741–1748.PubMedCrossRefGoogle Scholar
  45. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W & Haegeman G (1997) Gluco-corticoid-mediated repression of nuclear factor-κB-dependent transcription involves direct interference with transactivation. Proc. Natl. Acad. Sci. USA 94: 13504–13509.PubMedCrossRefGoogle Scholar
  46. de Crombrugghe B, Lefebvre V, Behringer RR, Bi W, Murakami S & Huang W (2000) Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 19: 389–394.PubMedCrossRefGoogle Scholar
  47. Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F, Hamsten A, Eriksson P & Nilsson J (1999) Very low-density lipoprotein activates nuclear factor-κB in endothelial cells. Circ. Res. 84: 1085–1094.PubMedCrossRefGoogle Scholar
  48. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, Wang Y, De Sanctis GT, Perkins DL & Finn PW (1999) NF-κB/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J. Immunol. 163: 6827–6833.PubMedGoogle Scholar
  49. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH, Patriotis C, Jenkins NA, Copeland NG, Kollias G & Tsichlis PN (2000) TNF-α induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103: 1071–1083.PubMedCrossRefGoogle Scholar
  50. Egan LJ & Sandborn WJ (1998) Inhibition of nuclear factor κB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology 115: 1295–1296.PubMedCrossRefGoogle Scholar
  51. Falvo JV, Uglialoro AM, Brinkman BM, Merika M, Parekh BS, Tsai EY, King HC, Morielli AD, Peralta EG, Maniatis T, Thanos D & Goldfeld AE (2000) Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor α gene promoter. Mol. Cell. Biol. 20: 2239–2247.PubMedCrossRefGoogle Scholar
  52. Farver CF, Raychaudhuri B, Buhrow LT, Connors MJ & Thomassen MJ (1998) Constitutive NF-κB levels in human alveolar macrophages from normal volunteers. Cytokine 10: 868–871.PubMedCrossRefGoogle Scholar
  53. Farzaneh-Far A, Davies JD, Braam LA, Spronk HM, Proudfoot D, Chan SW, O’Shaughnessy KM, Weissberg PL, Vermeer C & Shanahan CM (2001) A polymorphism of the human matrix γ-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J. Biol. Chem. 276: 32466–32473.PubMedCrossRefGoogle Scholar
  54. Feldmann M & Maini RN (2001) Anti-TNFα therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163–196.PubMedCrossRefGoogle Scholar
  55. Ferrer I, Marti E, Lopez E & Tortosa A (1998) NF-κB immunoreactivity is observed in association with βA4 diffuse plaques in patients with Alzheimer’s disease. Neuropathol. Appl. Neurobiol. 24: 271–277.PubMedCrossRefGoogle Scholar
  56. Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115: 182–205.PubMedCrossRefGoogle Scholar
  57. Foxwell B, Browne K, Bondeson J, Clarke C, de Martin R, Brennan F & Feldmann M (1998) Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc. Natl. Acad. Sci. USA 95: 8211–8215.PubMedCrossRefGoogle Scholar
  58. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K & Siebenlist U (1992) The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature 359: 339–342.PubMedCrossRefGoogle Scholar
  59. Franzoso G, Bours V, Azarenko V, Park S, Tomita-Yamaguchi M, Kanno T, Brown K & Siebenlist U (1993) The oncoprotein Bcl-3 can facilitate NF-κB-mediated transactivation by removing inhibiting p50 homodimers from select κB sites. EMBO J. 12: 3893–3901.PubMedGoogle Scholar
  60. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, Grinberg A, Tran T, Scharton-Kersten T, Anver M, Love P, Brown K & Siebenlist U (1998) Mice deficient in nuclear factor (NF)-κB/p52 present with defects in humoral responses germinal center reactions and splenic microarchitecture. J. Exp. Med. 187: 147–159.PubMedCrossRefGoogle Scholar
  61. Fujihara SM, Cleaveland JS, Grosmaire LS, Berry KK, Kennedy KA, Blake JJ, Loy J, Rankin BM, Ledbetter JA & Nadler SG (2000) A D-amino acid peptide inhibitor of NF-κB nuclear localization is efficacious in models of inflammatory disease. J. Immunol. 165: 1004–1012.PubMedGoogle Scholar
  62. Fujita T, Nolan GP, Liou HC, Scott ML & Baltimore D (1993) The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev. 7: 1354–1363.PubMedCrossRefGoogle Scholar
  63. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871–1875.PubMedCrossRefGoogle Scholar
  64. Geier DL & Miner PB (1992) New therapeutic agents in the treatment of inflammatory bowel disease. Am. J. Med. 93: 199–208.PubMedCrossRefGoogle Scholar
  65. Ghosh S, May MJ & Kopp EB (1998) NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225–260.PubMedCrossRefGoogle Scholar
  66. Giannoukakis N, Rudert WA, Trucco M & Robbins PD (2000) Protection of human islets from the effects of interleukin-1β by adenoviral gene transfer of an IκB repressor. J. Biol. Chem. 275: 36509–36513.PubMedCrossRefGoogle Scholar
  67. Grey ST, Arvelo MB, Hasenkamp W, Bach FH & Ferran C (1999) A20 inhibits cytokine-induced apoptosis and nuclear factor κB-dependent gene activation in islets. J. Exp. Med. 190: 1135–1146.PubMedCrossRefGoogle Scholar
  68. Grilli M, Goffi F, Memo M & Spano P (1996a) Interleukin-lβ and glutamate activate the NF-κB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J. Biol. Chem. 271: 15002–15007.PubMedCrossRefGoogle Scholar
  69. Grilli M, Pizzi M, Memo M & Spano P (1996b) Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science 274: 1383–1385.PubMedCrossRefGoogle Scholar
  70. Guerrini L, Blasi F & Denis-Donini S (1995) Synaptic activation of NF-κB by glutamate in cerebellar granule neurons in vitro. Proc. Natl. Acad. Sci. USA 92: 9077–9081.PubMedCrossRefGoogle Scholar
  71. Gveric D, Kaltschmidt C, Cuzner ML & Newcombe J (1998) Transcription factor NF-κB and inhibitor IκBα are localized in macrophages in active multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 57: 168–178.PubMedCrossRefGoogle Scholar
  72. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T & Cybulsky MI (2000) The NF-κB signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc. Natl. Acad. Sci. USA 97: 9052–9057.PubMedCrossRefGoogle Scholar
  73. Han Y, Runge MS & Brasier AR (1999) Angiotensin II induces interleukin-6 transcription in vascular Smooth muscle cells through pleiotropic activation of nuclear factor-κB transcription factors. Circ. Res. 84: 695–703.PubMedCrossRefGoogle Scholar
  74. Han Z, Boyle DL, Manning AM & Firestein GS (1998) AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197–208.PubMedCrossRefGoogle Scholar
  75. Handel ML, McMorrow LB & Gravallese EM (1995) Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum. 38: 1762–1770.PubMedCrossRefGoogle Scholar
  76. Hart LA, Krishnan VL, Adcock IM, Barnes PJ & Chung KF (1998) Activation and localization of transcription factor nuclear factor-κB in asthma. Am. J. Respir. Crit. Care Med. 158: 1585–1592.PubMedGoogle Scholar
  77. Hayashi T, Sekine T & Okamoto T (1993) Identification of a new serine kinase that activates NFκB by direct phosphorylation. J. Biol. Chem. 268: 26790–26795.PubMedGoogle Scholar
  78. Heck S, Bender K, Kullmann M, Gottlicher M, Herrlich P & Cato AC (1997) IκBα-independent downregulation of NF-κB activity by glucocorticoid receptor. EMBO J. 16: 4698–4707.PubMedCrossRefGoogle Scholar
  79. Hegazy DM, O’Reilly DA, Yang BM, Hodgkinson AD, Millward BA & Demaine AG (2001) NFκB polymorphisms and susceptibility to type 1 diabetes. Genes Immun. 2: 304–308.PubMedCrossRefGoogle Scholar
  80. Heimberg H, Heremans Y, Jobin C, Leemans R, Cardozo AK, Darville M & Eizirik DL (2001) Inhibition of cytokine-induced NF-κB activation by adenovirus-mediated expression of a NF-κB super-repressor prevents β-cell apoptosis. Diabetes 50: 2219–2224.PubMedCrossRefGoogle Scholar
  81. Hilliard B, Samoilova EB, Liu TS, Rostami A & Chen Y (1999) Experimental autoimmune encephalomyelitis in NF-κB-deficient mice: roles of NF-κB in the activation and differentiation of autoreactive T cells. J. Immunol. 163: 2937–2943.PubMedGoogle Scholar
  82. Ho E, Quan N, Tsai YH, Lai W & Bray TM (2001) Dietary zinc supplementation inhibits NFκB activation and protects against chemically induced diabetes in CD1 mice. Exp. Biol. Med. 226: 103–111.Google Scholar
  83. Hofman FM, Hinton DR, Johnson K & Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170: 607–612.PubMedCrossRefGoogle Scholar
  84. Hofmann MA, Schiekofer S, Kanitz M, Klevesath MS, Joswig M, Lee V, Morcos M, Tritschler H, Ziegler R, Wahl P, Bierhaus A & Nawroth PP (1998) Insufficient glycemie control increases nuclear factor-κB binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21: 1310–1316.PubMedCrossRefGoogle Scholar
  85. Hofmann MA, Schiekofer S, Isermann B, Kanitz M, Henkels M, Joswig M, Treusch A, Morcos M, Weiss T, Borcea V, Abdel Khalek AK, Amiral J, Tritschler H, Ritz E, Wahl P, Ziegler R, Bierhaus A & Nawroth PP (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42: 222–232.PubMedCrossRefGoogle Scholar
  86. Hohjoh H & Tokunaga K (2001) Allele-specific binding of the ubiquitous transcription factor OCT-1 to the functional single nucleotide polymorphism (SNP) sites in the tumor necrosis factor-α gene (TNFA) promoter. Genes Immun. 2: 105–109.PubMedCrossRefGoogle Scholar
  87. Igaz P, Falus A, Glaz E & Racz K (2000) Cytokines in diseases of the endocrine system. Cell Biol. Int 24: 663–668.PubMedCrossRefGoogle Scholar
  88. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A & Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat. Med. 3: 1285–1289.PubMedCrossRefGoogle Scholar
  89. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA & Kaltschmidt C (1997) Transcription factor NF-κB is activated in primary neurons by amyloid β peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc. Natl. Acad. Sci. USA 94: 2642–2647.PubMedCrossRefGoogle Scholar
  90. Kaltschmidt C, Kaltschmidt B, Neumann H, Wekerle H & Baeuerle PA (1994) Constitutive NF-κB activity in neurons. Mol. Cell. Biol. 14: 3981–3992.PubMedGoogle Scholar
  91. Kaltschmidt C, Kaltschmidt B & Baeuerle PA (1995) Stimulation of ionotropic glutamate receptors activates transcription factor NF-κB in primary neurons. Proc. Natl. Acad. Sci. USA 92: 9618–9622.PubMedCrossRefGoogle Scholar
  92. Karin M (1999) How NF-κB is activated: the role of the IκB kinase (IKK) complex. Oncogene 18: 6867–6874.PubMedCrossRefGoogle Scholar
  93. Karin M & Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NFκB activity. Annu. Rev. Immunol. 18: 621–663.PubMedCrossRefGoogle Scholar
  94. Keatings VM, Jatakanon A, Worsdell YM & Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. J. Respir. Crit. Care Med. 155: 542–548.PubMedGoogle Scholar
  95. Keifer JA, Guttridge DC, Ashburner BP & Baldwin AS (2001) Inhibition of NF-κB activity by thalidomide through suppression of βB kinase activity. J. Biol. Chem. 276: 22382–22387.PubMedCrossRefGoogle Scholar
  96. Keller JN, Kindy MS, Holtsberg FW, St Clair DK, Yen HC, Germeyer A, Steiner SM, Bruce-Keller AJ, Hutchins JB & Mattson MP (1998) Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production lipid peroxidation and mitochondrial dysfunction. J. Neurosci. 18: 687–689.PubMedGoogle Scholar
  97. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ & Leder P (1998) The death domain kinase RIP mediates the TNF-induced NF-κB signal. Immunity 8: 297–303.PubMedCrossRefGoogle Scholar
  98. Kieseier BC, Storch MK, Archelos JJ, Martino G & Hartung HP (1999) Effector pathways in immune mediated central nervous system demyelination. Curr. Opin. Neurol. 12: 323–336.PubMedCrossRefGoogle Scholar
  99. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE & Shulman GI (2001) Prevention of fat-induced insulin resistance by salicylate. J. Clin. Invest. 108: 437–446.PubMedGoogle Scholar
  100. Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K & Kwiatkowski D (1999) A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat. Genet. 22: 145–150.PubMedCrossRefGoogle Scholar
  101. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, Janeway CA, Medzhitov R & Flavell RA (2002) RICK/RIP2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194–199.PubMedCrossRefGoogle Scholar
  102. Kopp E & Ghosh S (1994) Inhibition of NF-κB by sodium salicylate and aspirin. Science 265: 956–959.PubMedCrossRefGoogle Scholar
  103. Kuhn R, Lohler J, Rennick D, Rajewsky K & Muller W (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263–274.PubMedCrossRefGoogle Scholar
  104. Kunsch C, Ruben SM & Rosen CA (1992) Selection of optimal κB/Rel DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for transcriptional activation. Mol. Cell. Biol. 12: 4412–4421.PubMedGoogle Scholar
  105. Landry DB, Couper LL, Bryant SR & Lindner V (1997) Activation of the NF-κB and IκB system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am. J. Pathol. 151: 1085–1095.PubMedGoogle Scholar
  106. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi BZ, Barshack I, Kopolovic J, Galun E, Bujard H & Ben-Neriah Y (2000) High susceptibility to bacterial infection but no liver dysfunction in mice compromised for hepatocyte NF-κB activation. Nat. Med. 6: 573–577.PubMedCrossRefGoogle Scholar
  107. Ley K (2001) Pathways and bottlenecks in the web of inflammatory adhesion molecules and chemoattractants. Immunol. Res. 24: 87–95.PubMedCrossRefGoogle Scholar
  108. Li N & Karin M (1999) Is NF-κB the sensor of oxidative stress? FASEB J. 13: 1137–1143.PubMedGoogle Scholar
  109. Li Q, Van Antwerp D, Mercurio F, Lee KF & Verma IM (1999a) Severe liver degeneration in mice lacking the βB kinase 2 gene. Science 284: 321–325.PubMedCrossRefGoogle Scholar
  110. Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R & Karin M (1999b) The IKKβ subunit of βB kinase (IKK) is essential for nuclear factor βB activation and prevention of apoptosis. J. Exp. Med. 189: 1839–1845.PubMedCrossRefGoogle Scholar
  111. Liu ZG, Hsu H, Goeddel DV & Karin M (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87: 565–576.PubMedCrossRefGoogle Scholar
  112. Majumdar S & Aggarwal BB (2001) Methotrexate suppresses NF-κB activation through inhibition of IκBa phosphorylation and degradation. J. Immunol. 167: 2911–2920.PubMedGoogle Scholar
  113. Manna SK, Mukhopadhyay A & Aggarwal BB (2000) Leflunomide suppresses TNF-induced cellular responses: effects on NF-κB activator protein-1: c-Jun N-terminal protein kinase and apoptosis. J. Immunol. 165: 5962–5969.PubMedGoogle Scholar
  114. Marienfeld R, Neumann M, Chuvpilo S, Escher C, Kneitz B, Avots A, Schimpl A & Serfling E (1997) Cyclosporin A interferes with the inducible degradation of NF-κB inhibitors but not with the processing of pl05/NF-κBl in T cells. Eur. J. Immunol. 27: 1601–1609.PubMedCrossRefGoogle Scholar
  115. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffhey K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C & Baeuerle PA (1996) Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39: 583–591.PubMedCrossRefGoogle Scholar
  116. Martin T, Cardarelli PM, Parry GC, Felts KA & Cobb RR (1997) Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-κB and AP-1. Eur. J. Immunol. 27: 1091–1097.PubMedCrossRefGoogle Scholar
  117. Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T & Akira S (1993) Transcription factors NF-IL6 and NF-κB synergistically activate transcription of the inflammatory cytokines interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. USA 90: 10193–10197.PubMedCrossRefGoogle Scholar
  118. Mattson MP, Goodman Y, Luo H, Fu W & Furukawa K (1997) Activation of NF-κB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J. Neurosci. Res. 49: 681–697.PubMedCrossRefGoogle Scholar
  119. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A & Brinckerhoff CE (2000) Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38: c-Jun N-terminal kinase and nuclear factor βB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 43: 801–811.PubMedCrossRefGoogle Scholar
  120. Meyer S, Kohler NG & Joly A (1997) Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation. FEBS Lett. 413: 354–358.PubMedCrossRefGoogle Scholar
  121. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS & Makarov SS (1998) NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA 95: 13859–13864.PubMedCrossRefGoogle Scholar
  122. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R & Nawroth PP (1999) The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors 10: 157–167.PubMedCrossRefGoogle Scholar
  123. Morigi M, Angioletti S, Imberti B, Donadelli R, Micheletti G, Figliuzzi M, Remuzzi A, Zoja C & Remuzzi G (1998) Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-κB-dependent fashion. J. Clin. Invest. 101: 1905–1915.PubMedCrossRefGoogle Scholar
  124. Mortensen RF (2001) C-reactive protein inflammation and innate immunity. Immunol. Res. 24: 163–176.PubMedCrossRefGoogle Scholar
  125. Murakami S, Lefebvre V & de Crombrugghe B (2000) Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-α. J. Biol. Chem. 275: 3687–3692.PubMedCrossRefGoogle Scholar
  126. Neish AS, Khachigian LM, Park A, Baichwal VR & Collins T (1995a) Spl is a component of the cytokine-inducible enhancer in the promoter of vascular cell adhesion molecule-1. J. Biol. Chem. 270: 28903–28909.PubMedCrossRefGoogle Scholar
  127. Neish AS, Read MA, Thanos D, Pine R, Maniatis T & Collins T (1995b) Endothelial interferon regulatory factor 1 cooperates with NF-κB as a transcriptional activator of vascular cell adhesion molecule 1. Mol. Cell. Biol. 15: 2558–2569.PubMedGoogle Scholar
  128. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH & Strober W (1996) Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 2: 998–1004.PubMedCrossRefGoogle Scholar
  129. Neurath MF & Pettersson S (1997) Predominant role of NF-κB p65 in the pathogenesis of chronic intestinal inflammation. Immunobiology 198: 91–98.PubMedCrossRefGoogle Scholar
  130. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR & Schreiber S (2000) Mechanisms in failure of infliximab for Crohn’s disease. Lancet 356: 1475–1479.PubMedCrossRefGoogle Scholar
  131. Norbiato G, Bevilacqua M, Vago T & Clerici M (1997) Glucocorticoids and Th-1: Th-2 type cytokines in rheumatoid arthritis osteoarthritis asthma atopic dermatitis and AIDS. Clin. Exp. Rheumatol. 15: 315–323.PubMedGoogle Scholar
  132. O’Neill LA & Kaltschmidt C (1997) NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 20: 252–258.PubMedCrossRefGoogle Scholar
  133. Pahan K & Schmid M (2000) Activation of nuclear factor-κB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 287: 17–20.PubMedCrossRefGoogle Scholar
  134. Pahl HL (1999) Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853–6866.PubMedCrossRefGoogle Scholar
  135. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J & Grisham MB (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95: 15671–15676.PubMedCrossRefGoogle Scholar
  136. Pan J & McEver RP (1995) Regulation of the human P-selectin promoter by Bcl-3 and specific homo-dimeric members of the NF-κB/Rel family. J. Biol. Chem. 270: 23077–23083.PubMedCrossRefGoogle Scholar
  137. Park BH & Park JW (2001) The protective effect of Amomum xanthoides extract against alloxan-induced diabetes through the suppression of NFκB activation. Exp. Mol. Med. 33: 64–68.PubMedGoogle Scholar
  138. Pierce JW, Read MA, Ding H, Luscinskas FW & Collins T (1996) Salicylates inhibit IκBα phosphorylation endothelial-leukocyte adhesion molecule expression and neutrophil transmigration. J. Immunol. 156: 3961–3969.PubMedGoogle Scholar
  139. Poligone B, Weaver DJ, Sen P, Baldwin AS & Tisch R (2002) Elevated NF-κB activation in non-obese diabetic mouse dendritic cells results in enhanced APC function. J. Immunol. 168: 188–196.PubMedGoogle Scholar
  140. Price SJ, Greaves DR & Watkins H (2001) Identification of novel functional genetic variants in the human matrix metalloproteinase-2 gene: role of Spl in allele-specific transcriptional regulation. J. Biol. Chem. 276: 7549–7558.PubMedCrossRefGoogle Scholar
  141. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF & Michel JB (2000) Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-κB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 20: 645–651.PubMedCrossRefGoogle Scholar
  142. Quan N, Ho E, La W, Tsai YH & Bray T (2001) Administration of NF-κB decoy inhibits pancreatic activation of NF-κB and prevents diabetogenesis by alloxan in mice. FASEB J. 15: 1616–1618.PubMedGoogle Scholar
  143. Roebuck KA (1999) Regulation of interleukin-8 gene expression. J. Interferon Cytokine Res. 19: 429–438.PubMedCrossRefGoogle Scholar
  144. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J & Gross V (1998) Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357–369.PubMedCrossRefGoogle Scholar
  145. Ruddle NH (1999) Lymphoid neo-organogenesis: lymphotoxin’s role in inflammation and development. Immunol. Res. 19: 119–125.PubMedCrossRefGoogle Scholar
  146. Rudolph D, Yeh WC, Wakeham A, Rudolph B, Nallainathan D, Potter J, Elia AJ & Mak TW (2000) Severe liver degeneration and lack of NF-κB activation in NEMO/IKKγ-deficient mice. Genes Dev. 14: 854–862.PubMedGoogle Scholar
  147. Saccani S, Pantano S & Natoli G (2001) Two waves of nuclear factor κB recruitment to target promoters. J. Exp. Med. 193: 1351–1359.PubMedCrossRefGoogle Scholar
  148. Saccani S, Pantano S & Natoli G (2002) p38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat Immunol. 3: 69–75.PubMedCrossRefGoogle Scholar
  149. Scheinman RI, Cogswell PC, Lofquist AK & Baldwin AS (1995a) Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270: 283–286.PubMedCrossRefGoogle Scholar
  150. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA & Baldwin AS (1995b) Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell. Biol. 15: 943–953.PubMedGoogle Scholar
  151. Schmidt AM, Yan SD, Wautier JL & Stern D (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84: 489–497.PubMedCrossRefGoogle Scholar
  152. Schmitz ML & Baeuerle PA (1991) The p65 subunit is responsible for the strong transcription activating potential of NF-κB. EMBO J. 10: 3805–3817.PubMedGoogle Scholar
  153. Schmitz ML, Bacher S & Kracht M (2001) IκB-independent control of NF-κB activity by modulatory phosphorylations. Trends Biochem. Sci. 26: 186–190.PubMedCrossRefGoogle Scholar
  154. Schreck R, Albermann K & Baeuerle PA (1992) Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun. 17: 221–237.PubMedCrossRefGoogle Scholar
  155. Schreiber S, Nikolaus S & Hampe J (1998) Activation of nuclear factor κB inflammatory bowel disease. Gut 42: 477–484.PubMedCrossRefGoogle Scholar
  156. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB & Abraham E (1996) Nuclear factor-κB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit. Care Med. 24: 1285–1292.PubMedCrossRefGoogle Scholar
  157. Seetharaman R, Mora AL, Nabozny G, Boothby M & Chen J (1999) Essential role of T cell NF-κB activation in collagen-induced arthritis. J. Immunol. 163: 1577–1583.PubMedGoogle Scholar
  158. Selmaj K, Raine CS, Cannella B & Brosnan CF (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87: 949–954.PubMedCrossRefGoogle Scholar
  159. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC & Karin M (2001) Activation by IKKα of a second evolutionary conserved NF-κB signaling pathway. Science 293: 1495–1499.PubMedCrossRefGoogle Scholar
  160. Sha WC, Liou HC, Tuomanen EI & Baltimore D (1995) Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 80: 321–330.PubMedCrossRefGoogle Scholar
  161. Shenkar R & Abraham E (1997) Hemorrhage induces rapid in vivo activation of CREB and NF-κB in murine intraparenchymal lung mononuclear cells. Am. J. Respir. Cell Mol. Biol. 16: 145–152.PubMedGoogle Scholar
  162. Simeonidis S, Liang S, Chen G & Thanos D (1997) Cloning and functional characterization of mouse IκBε. Proc. Natl. Acad. Sci. USA 94: 14372–14377.PubMedCrossRefGoogle Scholar
  163. Smith C, Andreakos E, Crawley JB, Brennan FM, Feldmann M & Foxwell BM (2001) NF-κB-inducing kinase is dispensable for activation of NF-κB in inflammatory settings but essential for lymphotoxin β receptor activation of NF-κB in primary human fibroblasts. J. Immunol. 167: 5895–5903.PubMedGoogle Scholar
  164. Stein B, Baldwin AS, Ballard DW, Greene WC, Angel P & Herrlich P (1993) Cross-coupling of the NF-κB p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J. 12: 3879–3891.PubMedGoogle Scholar
  165. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL & Goeddel DV (1999) Embryonic lethality liver degeneration and impaired NF-κB activation in IKK-β-deficient mice. Immunity 10: 421–429.PubMedCrossRefGoogle Scholar
  166. Terai K, Matsuo A & McGeer PL (1996) Enhancement of immunoreactivity for NF-κB in the hippocampal formation and cerebral cortex of Alzheimer’s disease. Brain Res. 735: 159–168.PubMedCrossRefGoogle Scholar
  167. Thanos D & Maniatis T (1995) Virus induction of human IFNβ gene expression requires the assembly of an enhanceosome. Cell 83: 1091–1100.PubMedCrossRefGoogle Scholar
  168. Thompson AB, Robbins RA, Romberger DJ, Sisson JH, Spurzem JR, Teschler H & Rennard SI (1995a) Immunological functions of the pulmonary epithelium. Eur. Respir. J. 8: 127–149.PubMedCrossRefGoogle Scholar
  169. Thompson JE, Phillips RJ, Erdjument-Bromage H, Tempst P & Ghosh S (1995b) IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 80: 573–582.PubMedCrossRefGoogle Scholar
  170. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y & Ochi T (1999) Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum. 42: 2532–2542.PubMedCrossRefGoogle Scholar
  171. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H & Takata I (1997) The effect of dexamethasone on the expression of activated NF-κB in adjuvant arthritis. Clin. Immunol. Immunopathol. 83: 173–178.PubMedCrossRefGoogle Scholar
  172. Udalova IA, Richardson A, Denys A, Smith C, Ackerman H, Foxwell B & Kwiatkowski D (2000) Functional consequences of a polymorphism affecting NF-κB p50–p50 binding to the TNF promoter region. Mol. Cell. Biol. 20: 9113–9119.PubMedCrossRefGoogle Scholar
  173. Udalova IA, Mott R, Field D & Kwiatkowski D (2002a) Quantitative prediction of NF-κB DNA-protein interactions. Proc. Natl. Acad. Sci. USA 99: 8167–8172.PubMedCrossRefGoogle Scholar
  174. Udalova IA, Richardson A, Ackerman H, Wordsworth P & Kwiatkowski D (2002b) Association of accelerated erosive rheumatoid arthritis with a polymorphism that alters NF-κB binding to the TNF promoter region. Rheumatology 41: 830–831.PubMedCrossRefGoogle Scholar
  175. Van Antwerp DJ, Martin SJ, Kafri T, Green DR & Verma IM (1996) Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787–789.PubMedCrossRefGoogle Scholar
  176. van Heel DA, Udalova IA, De Silva AP, McGovern DP, Kinouchi Y, Hull J, Lench NJ, Cardon LR, Carey AH, Jewell DP & Kwiatkowski D (2002) Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF-κB transcription factors. Hum. Mol. Genet. 11: 1281–1289.PubMedCrossRefGoogle Scholar
  177. Venkataraman L, Burakoff SJ & Sen R (1995) FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J. Exp. Med. 181: 1091–1099.PubMedCrossRefGoogle Scholar
  178. Wahl C, Liptay S, Adler G & Schmid RM (1998) Sulfasalazine: a potent and specific inhibitor of nuclear factor βB. J. Clin. Invest. 101: 1163–1174.PubMedCrossRefGoogle Scholar
  179. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ & Selkoe DJ (2002) Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535–539.PubMedCrossRefGoogle Scholar
  180. Wang CY, Mayo MW & Baldwin AS (1996) TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274: 784–787.PubMedCrossRefGoogle Scholar
  181. Wang D, Westerheide SD, Hanson JL & Baldwin AS (2000) Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J. Biol. Chem. 275: 32592–32597.PubMedCrossRefGoogle Scholar
  182. Weaver DJ, Poligone B, Bui T, Abdel-Motal UM, Baldwin AS & Tisch R (2001) Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IκB kinase. J. Immunol. 167: 1461–1468.PubMedGoogle Scholar
  183. Weih F, Durham SK, Barton DS, Sha WC, Baltimore D & Bravo R (1997) p50-NF-κB complexes partially compensate for the absence of RelB: severely increased pathology in p50−/−relB−/− double-knockout mice. J. Exp. Med. 185: 1359–1370.PubMedCrossRefGoogle Scholar
  184. Weingarten P, Bermak J & Zhou QY (2001) Evidence for non-oxidative dopamine cytotoxicity: potent activation of NF-κB and lack of protection by anti-oxidants. J. Neurochem. 76: 1794–1804.PubMedCrossRefGoogle Scholar
  185. Welch GN & Loscalzo J (1998) Homocysteine and atherothrombosis. N. Engl. J. Med. 338: 1042–1050.PubMedCrossRefGoogle Scholar
  186. Whiteside ST, Epinat JC, Rice NR & Israel A (1997) IκBε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 16: 1413–1426.PubMedCrossRefGoogle Scholar
  187. Whitley MZ, Thanos D, Read MA, Maniatis T & Collins T (1994) A striking similarity in the organization of the E-selectin and β interferon gene promoters. Mol. Cell. Biol. 14: 6464–6475.PubMedGoogle Scholar
  188. Wilckens T & De Rijk R (1997) Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol. Today 18: 418–424.PubMedCrossRefGoogle Scholar
  189. Wilson SH, Caplice NM, Simari RD, Holmes DR, Carlson PJ & Lerman A (2000) Activated nuclear factor-κB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148: 23–30.PubMedCrossRefGoogle Scholar
  190. Woodroofe MN & Cuzner ML (1993) Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. Cytokine 5: 583–588.PubMedCrossRefGoogle Scholar
  191. Wulczyn FG, Naumann M & Scheidereit C (1992) Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB. Nature 358: 597–599.PubMedCrossRefGoogle Scholar
  192. Xiao G, Harhaj EW & Sun SC (2001) NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7: 401–409.PubMedCrossRefGoogle Scholar
  193. Yan SD, Yan SF, Chen X, Fu J, Chen M, Kuppusamy P, Smith MA, Perry G, Godman GC, Nawroth P, Zweiter JL & Stern D (1995) Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β- peptide. Nat. Med. 1: 693–699.PubMedCrossRefGoogle Scholar
  194. Yang JP, Merin JP, Nakano T, Kato T, Kitade Y & Okamoto T (1995) Inhibition of the DNA-binding activity of NF-κB by gold compounds in vitro. FEBS Lett. 361: 89–96.PubMedCrossRefGoogle Scholar
  195. Yang L, Cohn L, Zhang DH, Homer R, Ray A & Ray P (1998) Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med. 188: 1739–1750.PubMedCrossRefGoogle Scholar
  196. Yin MJ, Yamamoto Y & Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396: 77–80.PubMedCrossRefGoogle Scholar
  197. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P & Ghosh S (1997) The transcriptional activity of NF-κB is regulated by the IκB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 89: 413–424.PubMedCrossRefGoogle Scholar
  198. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R & Boehncke WH (2002) Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 109: 671–679.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2003

Authors and Affiliations

  • E. Andreakos
    • 1
  • I. Udalova
    • 2
  • S. Sacre
    • 1
  • B. M. Foxwell
    • 1
  1. 1.Imperial College of Science, Technology and MedicineKennedy Institute of RheumatologyLondonUK
  2. 2.University Department of PaediatricsThe John Radcliffe HospitalOxfordUK

Personalised recommendations